TrialAmerican journal of respiratory and critical care medicine2023

Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials).

Antonio Anzueto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.